NCT02726750 2026-04-16
Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
M.D. Anderson Cancer Center
Recruiting
Clinical Trials
71 trialsNCT05640843 2026-04-16
A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
Memorial Sloan Kettering Cancer Center
Phase NA Recruiting
NCT06383143 2026-04-16
ProDigALIty
Fondazione IRCCS Policlinico San Matteo di Pavia
Recruiting
NCT02960555 2026-04-15
Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05136807 2026-04-15
Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
M.D. Anderson Cancer Center
Recruiting
NCT05361694 2026-04-09
TRANSFORMM
University of Miami
Recruiting
NCT07069751 2026-04-03
HiFi-MM
IRCCS San Raffaele
Phase NA Recruiting
NCT01177527 2026-03-30
Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
Dana-Farber Cancer Institute
Active not recruiting
NCT03236428 2026-03-27
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT06987708 2026-03-23
Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers
Hackensack Meridian Health
Phase NA Not yet recruiting
NCT02886065 2026-03-13
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
Massachusetts General Hospital
Phase 1 Active not recruiting
NCT05767359 2026-03-12
CAR- PRISM (PRecision Intervention Smoldering Myeloma)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT05014646 2026-03-05
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
City of Hope Medical Center
Phase 2 Active not recruiting
NCT07446777 2026-03-03
FAST-M
University of Miami
Phase NA Not yet recruiting
NCT06212323 2026-02-17
SPOTLIGHT
University of Utah
Recruiting
NCT02269592 2026-02-12
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Dana-Farber Cancer Institute
Recruiting
NCT04850846 2026-02-09
Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT02603887 2026-01-29
Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT03839459 2026-01-28
Denosumab for Smoldering Multiple Myeloma
University of Rochester
Phase 2 Completed
NCT07305662 2026-01-21
KORMED-PA Stud
Seoul National University Bundang Hospital
Phase NA Not yet recruiting
NCT06644625 2026-01-20
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
Wake Forest University Health Sciences
Recruiting
NCT04370483 2026-01-05
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma
City of Hope Medical Center
Phase EARLY_PHASE1 Active not recruiting
NCT03631043 2025-12-19
Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Completed
NCT05312255 2025-12-01
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Roswell Park Cancer Institute
Phase NA Recruiting
NCT03717844 2025-11-20
Registry for Adults With Plasma Cell Disorders (PCD's)
UNC Lineberger Comprehensive Cancer Center
Recruiting
NCT06055894 2025-11-13
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
Memorial Sloan Kettering Cancer Center
Phase NA Recruiting
NCT03616483 2025-11-10
The Indiana Myeloma Registry
Indiana University
Recruiting
NCT05565638 2025-09-25
PROFAST
Dana-Farber Cancer Institute
Phase NA Completed
NCT04776395 2025-09-15
Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
Emory University
Phase 2 Recruiting
NCT04920084 2025-09-09
A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
Memorial Sloan Kettering Cancer Center
Phase NA Active not recruiting
NCT05288062 2025-08-20
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma
Mayo Clinic
Phase 2 Terminated
NCT03951220 2025-08-19
LOOMIS
Oxford University Hospitals NHS Trust
Completed
NCT05831358 2025-08-17
Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program
Case Comprehensive Cancer Center
Phase NA Active not recruiting
NCT02916771 2025-08-11
Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT06365060 2025-08-06
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
Tufts Medical Center
Recruiting
NCT05841550 2025-08-05
The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma
Oslo University Hospital
Phase 1/2 Recruiting
NCT06762769 2025-08-01
MODIFY
University College, London
Phase 2 Recruiting
NCT00112827 2025-06-06
Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
City of Hope Medical Center
Phase 1/2 Completed
NCT05469893 2025-04-24
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT06895291 2025-03-30
ONCO-MRI
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Recruiting
NCT03792763 2025-02-11
DEFENCE
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 2 Completed
NCT05597345 2025-02-10
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
University of Rochester
Phase 2 Recruiting
NCT04023747 2025-02-03
OxPLoreD
University of Oxford
Active not recruiting
NCT04615572 2024-10-28
Screening to Improve Survival in AL Amyloidosis
Tufts Medical Center
Completed
NCT02298816 2024-10-03
HMvax-Regist
Wake Forest University Health Sciences
Withdrawn
NCT04731844 2024-07-12
Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
University of Rochester
Phase 2 Recruiting
NCT03289299 2023-12-12
ASCENT
International Myeloma Foundation
Phase 2 Active not recruiting
NCT03673826 2023-11-01
HO147SMM
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 2 Active not recruiting
NCT03591614 2023-08-18
Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Withdrawn
NCT02903381 2023-06-13
A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
Dana-Farber Cancer Institute
Phase 2 Completed